Cetuximab biobetter is under clinical development by Shanghai Henlius Biotech and currently in Phase II for Nasopharyngeal Cancer. According to GlobalData, Phase II drugs for Nasopharyngeal Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Cetuximab biobetter LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cetuximab biobetter overview
HLX-07 is under development for the treatment of solid tumors including squamous cell carcinoma of the head and neck, squamous non-small cell lung cancer, small cell lung cancer, metastatic colorectal cancer, esophageal squamous cell carcinoma, non-squamous non-small cell lung cancer, hepatocellular carcinoma and cutaneous squamous cell carcinoma, nasopharyngeal cancer and advanced metastatic gastric cancer including gastroesophageal junction cancer. It is a humanized monoclonal antibody biobetter. It is administered through parenteral route. The drug candidate acts by targeting epidermal growth factor receptor (EGFR). It was also under development for the treatment of lung cancer.
See Also:
Shanghai Henlius Biotech overview
Shanghai Henlius Biotech (Henlius), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co Ltd, is a biopharmaceutical company, which includes research, development, production and marketing of monoclonal antibody products. It develops medicine for oncology, autoimmune and ophthalmic diseases. The company offers products such as rituximab injection for treating chronic lymphocytic leukemia and non-Hodgkin lymphoma; trastuzumab for breast cancer, metastatic gastric cancer and metastatic breast cancer; and adalimumab injection for ankylosing spondylitis, rheumatoid arthritis, plaque psoriasis and uveitis. It also offers bevacizumab injection and serplulimab injection. The company operates research and development centers in Shanghai, China and the US. Henlius is headquartered in Shanghai, China.
For a complete picture of Cetuximab biobetter’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.